Evidence map›Paper›PMID 39497927›Full record

ArticleClinical Medicine Insights. Oncology2024

Roles of

Hager A Mahmoud, Shahira Ka Botros, Abdelhamid Mohamed Fouad, Mahmoud M Kamel, Rania S Abdel Aziz

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical Medicine Insights. Oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Hager A MahmoudClinical Pathology Department, National Cancer Institute, Cairo University, Cairo, Egypt.
Shahira Ka BotrosClinical Pathology Department, Faculty of Medicine, Cairo University, Cairo, Egypt.
Abdelhamid Mohamed FouadMedical Oncology Department, National Cancer Institute, Cairo University, Cairo, Egypt.
Mahmoud M KamelClinical Pathology Department, National Cancer Institute, Cairo University, Cairo, Egypt.ORCID https://orcid.org/0000-0003-0264-3096
Rania S Abdel AzizClinical Pathology Department, National Cancer Institute, Cairo University, Cairo, Egypt.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Acute myeloid leukemia (AML) has a heterogeneous molecular profile, clinical presentations, and response to treatments and outcomes. DNA methylation is conducted by DNA methyltransferases including DNMT3B. Poly ADP-ribose polymerase 1 belongs to a family of enzymes that mediate important cellular processes including DNA repair, transcription, and cell death/cell proliferation, and it is involved in the development, spread, treatment, and prognosis of some cancers. The objective of this study is to assess the impact of Methods: This study included 67 Egyptian CN-AML patients in addition to 8 healthy bone marrow donors. Measurement of Result: Expression of both Conclusion: Our findings highlight the importance of considering

Indexed as

Acute myeloid leukemiaDNMT3Bgene expressionPARP1real-time PCR

Identifiers

PMID39497927
PMCPMC11533204

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.